

Validation Report for **adoptr** package

Kevin Kunzmann & Maximilian Pilz

2019-03-31

Contents

1	Introduction	5
1.1	Concept	5
1.2	Local validation	5
1.3	Brief Introduction to Two-Stage Designs	5
1.4	Validation strategy	6

Chapter 1

Introduction

1.1 Concept

The goal of `adoptrValidation` is to provide a comprehensive suit of test for the `adoptr` package. The package is not directly intended to be used but to automatically deploy a weekly validation report via github pages to <https://kkmann.github.io/adoptrValidation/>. The report is implemented as a set of vignettes which are compiled into a static web page using `pkgdown`. For details on the class of supported designs, see <https://github.com/kkmann/adoptr>.

1.2 Local validation

...

1.3 Brief Introduction to Two-Stage Designs

In `adoptrValidation` a suitable set of cases is tested in order to validate the performance of the package `adoptr`. This package allows to compute optimal designs (adaptive two-stage, group-sequential two-stage and one-stage) for normally distributed data. For a treatment group T and a control group C where the observations $X_i^T \sim \mathcal{N}(\mu_T, \sigma^2)$, $X_i^C \sim \mathcal{N}(\mu_C, \sigma^2)$ the following hypotheses are tested:

$$\mathcal{H}_0 : \delta := \mu_T - \mu_C \leq 0 \text{ v.s. } \mathcal{H}_\infty : \delta > 0.$$

The power of a test procedure is computed on an alternative effect size $\delta_1 > 0$ where a prior distribution $\delta_1 \sim \pi(\vartheta, \tau^2)$ is imaginable.

The trial evaluation happens as follows. After n_1 patients (per group) finished the trial an interim analysis is conducted. The interim test statistic Z_1 for a standard z-test is computed and the trial is stopped early for futility, if $Z_1 < c_f$. If $Z_1 > c_e$ the null hypothesis is rejected and the trial is stopped early for efficacy. Otherwise, i.e. if $c_f \leq Z_1 \leq c_e$, the trial enters in the second stage. Due to the adaptiveness of the trial design, the stage-two sample size is a function of Z_1 , i.e. $n_2(Z_1)$. Also the final rejection boundary c_2 depends on Z_1 . At the final analysis the stage-two test statistic Z_2 is computed and the null hypothesis is rejected if $Z_2 > c_2(Z_1)$.

A design D is a five-tuple consisting of the first-stage sample size n_1 , early stopping boundaries c_f (futility) and c_e (efficacy) and stage-two functions $n_2(\cdot)$ (sample size) and $c_2(\cdot)$ (rejection boundary). All these

elements can be computed optimally in **adoptr**. The incorporation of continuous priors is possible as well as including conditional and unconditional constraints.

Given a design D and a objective function f the default setting in [adoptr] is the following.

min	$f(D)$
such that	Type One Error Rate $\leq \alpha$
and	Power $\geq 1 - \beta$

Often in clinical practice one is not willing to enter in a second stage when the conditional power (i.e., the probability to reject at the final analysis given the first-stage results) is too low or too high because in these cases the stage-two result is likely predictable. Therefore, introducing conditional power constraints of the form

$$1 - \beta_2 \leq \text{Conditional Power}(z_1, D) \leq 1 - \beta_3$$

may be desirable and are supported by **adoptr**.

In **adoptrValidation** different scenarios are investigated. Each scenario is determined by the assumed effect size δ_1 and its prior distribution π . In each scenario, different tests are performed. All tests are indicated by a bullet point.

1.4 Validation strategy

adoptrValidation essentially extends the test suit of **adoptr** to cover more different scenarios. In order to generate a proper validation report the test Variants are not managed using a unit testing framework like testthat but are directly included in a set of vignettes (one per sceanrio). These vignettes are automatically built and published (here) once per week using pkgdown to keep the validation report up to date with the latest CRAN release [TODO: we currently use our master!]. The overall failure/pass status of the latest build can be checked using the Travis-CI badge. In the following, all Scenarios and their respective sub-Variants are outlined. **Scenarios** are defined by the joint distribution of the test statistic and the location parameter, while **Variants** are given by the respective optimization problem (objective, constraints).

1.4.1 Technical Setup

Initially, the both packages are loaded and the seed for simulation is set. Additionally, the options for optimization are modified by increasing the maximum number of evaluations to ensure convergence.

```
library(adoptr)
library(tidyverse)

# load custom functions in folder subfolder '/R'
for (nm in list.files("R", pattern = "\\.[RrSsQq]"))
  source(file.path("R", nm))

# define seed value
seed <- 42

# define custom tolerance and iteration limit for nloptr
opts = list(
  algorithm = "NLOPT_LN_COBYLA",
  xtol_rel = 1e-5,
```

```
maxeval    = 50000
)
```

1.4.2 Scenario I

This is the default scenario.

- **Data distribution:** Two-armed trial with normally distributed test statistic
- **Prior:** $\delta \sim \delta_{0.4}$
- **Null hypothesis:** $\mathcal{H}_0 : \delta \leq 0$

1.4.2.1 Variant I.1: Minimizing Expected Sample Size under the Alternative

- **Objective:** $ESS := E[n(X_1) | \delta = 0.4]$
- **Constraints:**
 1. $Power := \Pr[c_2(X_1) < X_2 | \delta = 0.4] \geq 0.8$
 2. $TOER := \Pr[c_2(X_1) < X_2 | \delta = 0.0] \leq 0.025$
 3. Three variants: two-stage, group-sequential, one-stage.
- **Formal tests:**
 1. All three **adoptr** variants (two-stage, group-sequential, one-stage) comply with constraints. Internally validated by testing vs. simulated values of the power curve at respective points.
 2. ESS of optimal two-stage design is lower than ESS of optimal group-sequential one and that is in turn lower than the one of the optimal one-stage design.
 3. ESS of optimal group-sequential design is lower than ESS of externally computed group-sequential design using the `rpact` package.
 4. Are the ESS values obtained from simulation the same as the ones obtained by using numerical integration via `adoptr::evaluate`?
 5. Is $n()$ of the optimal two-stage design monotonously decreasing on continuation area?

1.4.2.2 Variant I.2: Minimizing Expected Sample Size under the Null Hypothesis

- **Objective:** $ESS := E[n(X_1) | \delta = 0.0]$
- **Constraints:**
 1. $Power := \Pr[c_2(X_1) < X_2 | \delta = 0.4] \geq 0.8$
 2. $TOER := \Pr[c_2(X_1) < X_2 | \delta = 0.0] \leq 0.025$
- **Formal tests:**
 1. Validate constraint compliance by testing vs. simulated values of the power curve at respective points.
 2. $n()$ of optimal design is monotonously increasing on continuation area. TODO
 3. ESS of optimal two-stage design is lower than ESS of externally computed group-sequential design using the `rpact` package.
 4. Are the ESS values obtained from simulation the same as the ones obtained by using numerical integration via `adoptr::evaluate`?

1.4.2.3 Variant I.3: Conditional Power Constraint

- **Objective:** $ESS := E[n(X_1) | \delta = 0.4]$
- **Constraints:**
 1. $Power := \Pr[c_2(X_1) < X_2 | \delta = 0.4] \geq 0.8$
 2. $TOER := \Pr[c_2(X_1) < X_2 | \delta = 0.0] \leq 0.025$

3. $CP := \Pr[c_2(X_1) < X_2 | \delta = 0.4, X_1 = x_1] \geq 0.7$ for all $x_1 \in (c_1^f, c_1^e)$
- **Formal tests:**
 1. Check *Power* and *TOER* constraints with simulation. Check *CP* constraint on three different values of x_1 in (c_1^f, c_1^e)
 2. Are the *CP* values at the three test-pivots obtained from simulation the same as the ones obtained by using numerical integration via `adoptr::evaluate`?
 3. Is *ESS* of optimal two-stage design with *CP* constraint higher than *ESS* of optimal two-stage design without this constraint?

1.4.3 Scenario II

Similar in scope to Scenario I, but with a continuous Gaussian prior on δ .

- **Data distribution:** Two-armed trial with normally distributed test statistic
- **Prior:** $\delta \sim \mathcal{N}(0.4, 3)$
- **Null hypothesis:** $\mathcal{H}_0 : \delta \leq 0$

1.4.3.1 Variant II.1: Minimizing Expected Sample Size

- **Objective:** $ESS := E[n(X_1)]$
- **Constraints:**
 1. $Power := \Pr[c_2(X_1) < X_2 | \delta > 0.0] \geq 0.8$
 2. $TOER := \Pr[c_2(X_1) < X_2 | \delta = 0.0] \leq 0.025$
 3. Three variants: two-stage, group-sequential, one-stage.
- **Formal tests:**
 1. All designs comply with type one error rate constraints (tested via simulation).
 2. *ESS* of optimal two-stage design is lower than *ESS* of optimal group-sequential one and that is in turn lower than the one of the optimal one-stage design.

1.4.3.2 Variant II.2: Minimizing Expected Sample Size under the Null hypothesis

- **Objective:** $ESS := E[n(X_1) | \delta \leq 0]$
- **Constraints:**
 1. $Power := \Pr[c_2(X_1) < X_2 | \delta > 0.0] \geq 0.8$
 2. $TOER := \Pr[c_2(X_1) < X_2 | \delta = 0.0] \leq 0.025$
- **Formal tests:**
 1. Does the design comply with *TOER* constraint (via simulation)?
 2. Check *CP* constraint on three different values of x_1 in (c_1^f, c_1^e)
 3. TODO: Is the sample size function monotonously increasing?
 4. Is *ESS* lower than expected sample size under the null hypothesis for the optimal two stage design from Variant II-1?

1.4.3.3 Variant II.3: Conditional Power Constraint

- **Objective:** $ESS := E[n(X_1)]$
- **Constraints:**
 1. $Power := \Pr[c_2(X_1) < X_2 | \delta > 0.0] \geq 0.8$
 2. $TOER := \Pr[c_2(X_1) < X_2 | \delta = 0.0] \leq 0.025$
 3. $CP := \Pr[c_2(X_1) < X_2 | \delta > 0.0, X_1 = x_1] \geq 0.7$ for all $x_1 \in (c_1^f, c_1^e)$
- **Formal tests:**

1. Check *TOER* constraint with simulation. Check *CP* constraint on three different values of x_1 in (c_1^f, c_1^e)
2. Is *ESS* of optimal two-stage design with *CP* constraint higher than *ESS* of optimal two-stage design without the constraint?

1.4.4 Scenario III:

- **Data distribution:** Two-armed trial with normally distributed test statistic
- **Prior:** sequence of uniform distributions $\delta \sim \text{Unif}(0.4 - \Delta_i, 0.4 + \Delta_i)$ around 0.4 with $\Delta_i = (3 - i)/10$ for $i = 0 \dots 3$. I.e., for $\Delta_3 = 0$ reduces to a point prior on $\delta = 0.4$.
- **Null hypothesis:** $\mathcal{H}_0 : \delta \leq 0$

1.4.4.1 Variant III.1: Convergence under Prior Concentration

- **Objective:** $ESS := E[n(X_1)]$
- **Constraints:**
 1. $Power := \Pr[c_2(X_1) < X_2 | \delta > 0.0] \geq 0.8$
 2. $TOER := \Pr[c_2(X_1) < X_2 | \delta = 0.0] \leq 0.025$
- **Formal tests:**
 1. Simulated type one error rate is compared to *TOER* constraint for each design.
 2. Number of iterations are checked against default maximum to ensure proper convergence.
 3. TODO: *ESS* decreases with prior variance.

Additionally, the designs are compared graphically. Inspect the plot to see convergence pattern.

1.4.5 Scenario IV: Smaller effect size, larger trials.

1.4.5.1 Variant IV.1: Minimizing Expected Sample Size under the Alternative

- **Objective:** $ESS := E[n(X_1) | \delta = 0.2]$
- **Constraints:**
 1. $Power := \Pr[c_2(X_1) < X_2 | \delta = 0.2] \geq 0.8$
 2. $TOER := \Pr[c_2(X_1) < X_2 | \delta = 0.0] \leq 0.025$
 3. Three variants: two-stage, group-sequential, one-stage.
- **Formal tests:**
 1. All three adoptr variants (two-stage, group-sequential, one-stage) comply with constraints. Internally validated by testing vs. simulated values of the power curve at respective points.
 2. *ESS* of optimal two-stage design is lower than *ESS* of optimal group-sequential one and that is in turn lower than the one of the optimal one-stage design.
 3. *ESS* of optimal group-sequential design is lower than *ESS* of externally computed group-sequential design using the rpact package.
 4. Are the *ESS* values obtained from simulation the same as the ones obtained by using numerical integration via `adoptr::evaluate`?
 5. Is $n()$ of the optimal two-stage design monotonously decreasing on continuation area? TODO

1.4.5.2 Variant IV.2: Increasing Power

- **Objective:** $ESS := E[n(X_1) | \delta = 0.2]$
- **Constraints:**
 1. $Power := \Pr[c_2(X_1) < X_2 | \delta = 0.2] \geq 0.9$
 2. $TOER := \Pr[c_2(X_1) < X_2 | \delta = 0.0] \leq 0.025$

- 3. Three variants: two-stage, group-sequential, one-stage.
- **Formal tests:**
 1. Does the design respect all constraints (via simulation)?
 2. ESS of optimal two-stage design is lower than ESS of optimal group-sequential one and that is in turn lower than the one of the optimal one-stage design.
 3. ESS of optimal group-sequential design is lower than ESS of externally computed group-sequential design using the rpact package.
 4. Are the ESS values obtained from simulation the same as the ones obtained by using numerical integration via `adoptr::evaluate`?
 5. Is $n()$ of the optimal two-stage design monotonously decreasing on continuation area? TODO

1.4.5.3 Variant IV.3: Increasing Maximal Type One Error Rate

- **Objective:** $ESS := E[n(X_1) | \delta = 0.2]$
- **Constraints:**
 1. $Power := Pr[c_2(X_1) < X_2 | \delta = 0.2] \geq 0.8$
 2. $TOER := Pr[c_2(X_1) < X_2 | \delta = 0.0] \leq 0.05$
 3. Three variants: two-stage, group-sequential, one-stage.
- **Formal tests:**
 1. Does the design respect all constraints (via simulation)?
 2. ESS of optimal two-stage design is lower than ESS of optimal group-sequential one and that is in turn lower than the one of the optimal one-stage design.
 3. ESS of optimal group-sequential design is lower than ESS of externally computed group-sequential design using the rpact package.
 4. Are the ESS values obtained from simulation the same as the ones obtained by using numerical integration via `adoptr::evaluate`?
 5. Is $n()$ of the optimal two-stage design monotonously decreasing on continuation area? TODO

1.4.6 Scenario V: Single-arm design, medium effect size.

- **Data distribution:** One-armed trial with normally distributed test statistic
- **Prior:** $\delta \sim \delta_{0.3}$
- **Null hypothesis:** $\mathcal{H}_0 : \delta \leq 0$

1.4.6.1 Variant V.1: Sensitivity to Integration Order

- **Objective:** $ESS := E[n(X_1) | \delta = 0.3]$
- **Constraints:**
 1. $Power := Pr[c_2(X_1) < X_2 | \delta = 0.3] \geq 0.8$
 2. $TOER := Pr[c_2(X_1) < X_2 | \delta = 0.0] \leq 0.025$
 3. Three variants: integration order 5, 8, 11 two-stage designs [TODO: maybe more?].
- **Formal tests:**
 1. Do all designs respect all constraints (via simulation)?
 2. Do all designs converge within the respective iteration limit?
 3. Does constraint compliance get better with increased order?
 4. Does the simulated ESS get better with increased order?

1.4.6.2 Variant V.2: Utility Maximization

- **Objective:** $\lambda Power - ESS := \lambda Pr[c_2(X_1) < X_2 | \delta = 0.3] - E[n(X_1) | \delta = 0.3]$. for $\lambda = 100$ and 200

- **Constraints:**
 1. $TOER := \Pr[c_2(X_1) < X_2 \mid \delta = 0.0] \leq 0.025$
- **Formal tests:**
 1. Do both designs respect the type one error rate constraint (via simulation)?
 2. Is the power of the design with larger λ larger?

1.4.6.3 Variant V.3: n_1 penalty

- **Objective:** $ESS := E[n(X_1) \mid \delta = 0.3] + \lambda n_1$ for $\lambda = 0.05$ and 0.2 .
- **Constraints:**
 1. $TOER := \Pr[c_2(X_1) < X_2 \mid \delta = 0.0] \leq 0.025$
 2. $Power := \Pr[c_2(X_1) < X_2 \mid \delta = 0.3] \geq 0.8$
- **Formal tests:**
 1. Is n_1 for the optimal design smaller than the order-5 design in V.1?

1.4.6.4 Variant V.4: n_2 penalty

- **Objective:** $ESS := E[n(X_1) \mid \delta = 0.3] + \text{AverageN2}$
- **Constraints:**
 1. $TOER := \Pr[c_2(X_1) < X_2 \mid \delta = 0.0] \leq 0.025$
 2. $Power := \Pr[c_2(X_1) < X_2 \mid \delta = 0.3] \geq 0.8$
- **Formal tests:**
 1. Is the AverageN2 for the optimal design smaller than for the order-5 design in V.1?